1. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers
- Author
-
Chel Hun Choi, Jae Ryoung Hwang, Taebum Lee, Jeong Woo Oh, Yeri Lee, Hyung Jun Ahn, Myeong Seon Kim, Joon Seol Bae, Sang Yong Song, Duk-Soo Bae, Woong-Yang Park, Jeong-Won Lee, Jihye Kim, E Sun Paik, Anil K. Sood, Young Jae Cho, Jason K. Sa, Ja Yeon Kim, Tae-Joong Kim, Hee Dong Han, Yun Jee Seo, Do Hyun Nam, Ji Yoon Ryu, Raul Rabadan, Harim Koo, Soo Young Jeong, Jin Ku Lee, Yoo-Young Lee, Hee Jin Cho, Nam Gu Her, Yong Jae Shin, Byoung-Gie Kim, Jung Joo Choi, and Hyun Soo Kim
- Subjects
Drug ,lcsh:QH426-470 ,Genital Neoplasms, Female ,media_common.quotation_subject ,Gynecologic malignancy ,Antineoplastic Agents ,Biology ,medicine.disease_cause ,Olaparib ,Metastasis ,Transcriptome ,chemistry.chemical_compound ,Biomarkers, Tumor ,medicine ,Humans ,Precision Medicine ,lcsh:QH301-705.5 ,media_common ,TP53 mutations ,Research ,Pharmacogenomic analysis ,ID2 ,medicine.disease ,Human genetics ,Pharmacogenomic Testing ,lcsh:Genetics ,PARP inhibitor ,lcsh:Biology (General) ,chemistry ,Pharmacogenomics ,Cancer research ,Female ,Carcinogenesis - Abstract
Background Gynecologic malignancy is one of the leading causes of mortality in female adults worldwide. Comprehensive genomic analysis has revealed a list of molecular aberrations that are essential to tumorigenesis, progression, and metastasis of gynecologic tumors. However, targeting such alterations has frequently led to treatment failures due to underlying genomic complexity and simultaneous activation of various tumor cell survival pathway molecules. A compilation of molecular characterization of tumors with pharmacological drug response is the next step toward clinical application of patient-tailored treatment regimens. Results Toward this goal, we establish a library of 139 gynecologic tumors including epithelial ovarian cancers (EOCs), cervical, endometrial tumors, and uterine sarcomas that are genomically and/or pharmacologically annotated and explore dynamic pharmacogenomic associations against 37 molecularly targeted drugs. We discover lineage-specific drug sensitivities based on subcategorization of gynecologic tumors and identify TP53 mutation as a molecular determinant that elicits therapeutic response to poly (ADP-Ribose) polymerase (PARP) inhibitor. We further identify transcriptome expression of inhibitor of DNA biding 2 (ID2) as a potential predictive biomarker for treatment response to olaparib. Conclusions Together, our results demonstrate the potential utility of rapid drug screening combined with genomic profiling for precision treatment of gynecologic cancers.
- Published
- 2019
- Full Text
- View/download PDF